Related Experiment Videos

Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy

Su-Mi Kim1, Young-Wook Choi, Hwa-Young Seok

  • 1Division of Nephrology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Seoul, Korea.

Nephron. Experimental Nephrology
|January 12, 2013
PubMed
Abstract

Insights

Lowering serum uric acid with allopurinol may prevent kidney damage in type 2 diabetes. This study shows reduced profibrogenic changes and improved kidney markers in diabetic mice treated with allopurinol, suggesting a therapeutic benefit.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Tubulointerstitial fibrosis, driven by transforming growth factor-β1 (TGF-β1), is key in chronic kidney disease progression.
  • Hyperuricemia is linked to increased TGF-β1 and tubulointerstitial injury.
  • Type 2 diabetic nephropathy involves TGF-β1-induced profibrogenic changes.

Purpose of the Study:

  • To investigate if lowering serum uric acid can reduce TGF-β1-induced profibrogenic tubular changes in type 2 diabetic nephropathy.
  • To test the hypothesis that allopurinol, a uric acid-lowering drug, has protective effects in diabetic kidney disease.

Main Methods:

  • KK-A(y)/Ta mice (type 2 diabetes model) were treated with or without allopurinol in drinking water.
  • Normal rat kidney epithelial cells were stimulated with uric acid, with or without allopurinol, in vitro.
  • Key markers of fibrosis, epithelial-mesenchymal transition, and signaling pathways were analyzed.

Main Results:

  • Allopurinol treatment reduced albuminuria and attenuated TGF-β1-induced profibrogenic tubular changes in diabetic mice.
  • Allopurinol inhibited TGF-β1-induced Smad pathway activation in tubular cells.
  • Effects included increased E-cadherin and decreased vimentin and α-smooth muscle actin; uric acid-induced TGF-β1 upregulation was linked to MAPK signaling.

Conclusions:

  • This study provides the first evidence that reducing serum uric acid can prevent profibrogenic progression in type 2 diabetic kidney disease.
  • Lowering serum uric acid may represent a novel therapeutic strategy for managing type 2 diabetic kidney disease.
  • Targeting hyperuricemia could be beneficial in preventing diabetic kidney disease progression.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...